Vector Control, Saving Lives
  • Creating a future free from malaria

    Creating a future free from malaria

  • Fighting vector-borne disease

  • Working in partnership

  • Malaria can be stopped

  • Every person matters

  • Photo of girls in Burkina Faso

    No child should die from malaria

  • Creating solutions to insect-borne disease

  • World Mosquito Day—Stop malaria killing children

  • Building partnerships across the world

  • Protecting people, increasing prosperity

Our story

At IVCC we’re passionate about finishing the job we were set up to do. These videos tell some of the story.

  • Good Laboratory Practice

    IVCC is working to bring all its vector control trial sites in Africa up to Good Laboratory Practice standards of quality control. This will ensure that the data produced by each trial site will be acceptable globally.
  • Heroic Chemistry

    Scientists who work in public health are the unsung heroes of our age. In Africa, local scientists are working to make their countries a safer and healthier place to live. Together scientists are fighting the battle against malaria. This video is a tribute to the scientists who are working with IVCC to develop effective new vector control tools. Together we will defeat malaria.
  • Introducing IVCC: fighting malaria

    IVCC was set up to find new ways to control the mosquitoes that transmit malaria, dengue, and other deadly diseases. This is our story.
  • What is Vector Control?

    What exactly is Vector Control and why is it so important?
  • Why do we need 3 new anti-malaria insecticides?

    Insecticide treated bednets and indoor residual spraying have dramatically reduced malaria deaths and sickness. But they depend on only four classes of insecticide for IRS and just one, the pyrethroids, for bednets. Find out why we need more than one new class of anti-malaria insecticide to replace them.
  • Insecticide Resistance: the Tipping Point

    Anti-malarial insecticides are widely recognised as one of the most important elements in the battle against malaria. But mosquitoes are developing resistance to the insecticides that are available, and this is becoming a serious issue. That's why developing new anti-malarial insecticides quickly is so essential to world health.
  • Every Person Matters

    The work we are doing is vital. Lives are being saved now through Vector Control, and many lives are at risk if we do not achieve our goals. Every life saved makes a difference. Every life lost diminishes us all—each one could be a Mandela, a Mozart, or an Einstein. Every person matters: every single one.
  • Celebrating 10 years of developing new vector control tools

    October 2015 marks 10 years since the first funding contract was signed with the Bill and Melinda Gates Foundation (BMGF). IVCC was set up to develop new public health insecticides to fight malaria. Insecticide treated bed nets and indoor residual spraying has accounted for 78% of the malaria cases averted over the past 15 years, according to a study by leading academics (Bhatt et al As there has been no new public health insecticide for over 30 years the situation was critical. Over the last 10 years IVCC has worked together with leading agro-chemical companies to develop new insecticides that will continue the essential work of vector control. With continued funding from BMGF and additional support from UKAID, USAID and the Swiss Agency for Development and Cooperation we're about to see several new compounds enter the final stages of development. Together with our partners throughout the world we are seeking to speed up the time when these new insecticides can be operational saving lives in the field. This film is a modest acknowledgment of this major stage in our journey. And it is a thank you for the commitment and vision of our funders, and the skill and dedication of our scientific partners.
  • Bridging the Gap

    IVCC together with its agrochemical partners has identified three totally new anti-malarial insecticides and is to bring them into final development. But there is a funding gap of $50-100 million to finish the job. Many companies have business interests and major markets in the areas affected by malaria and healthy employees, customers and communities are really important to them. So are the Corporate Social Responsibility benefits enough to get a handful of companies to contribute $5-10 million over a few years to help bridge the gap?